Advanced merger talks to combine British medical technology firm Smith & Nephew with Johnson & Johnson’s orthopaedics division have collapsed following an irreconcilable dispute over who would lead the proposed $34 billion combined entity, according to a report by Win Country citing the Financial Times.
The negotiations had reached an advanced stage, with both multinational companies largely aligned on key financial terms and the overarching transaction structure. The ambitious reverse merger would have valued J&J’s hip and knee replacement unit at up to $22 billion—nearly double Smith & Nephew’s £9.4 billion ($12.58 billion) market capitalization at the time. Under the terms being discussed before the breakdown, J&J shareholders would have held a 50.1% stake in the newly formed enterprise.
Leadership Dispute and Governance Impasse
The talks fell apart at the final hour after Smith & Nephew rejected J&J’s push to install Namal Nawana as the chief executive of the merged company, KuCoin reported based on financial media coverage. Nawana previously served as CEO of Smith & Nephew for 18 months before stepping down in 2019, and currently heads J&J’s orthopaedics division. J&J favored Nawana to steer the combined group, pointing to his recent performance improvements within the division.
Conversely, Smith & Nephew insisted that its current chief executive, Deepak Nath, remain in charge. Smith & Nephew Chair Rupert Soames made Nath’s retention a non-negotiable condition, a firm stance that ultimately caused J&J’s interest to cool. Furthermore, corporate governance hurdles regarding executive compensation played a contributing role; Smith & Nephew has historically noted challenges with UK and US pay structures, though the British firm recently moved to raise Nath’s maximum compensation package to $15.3 million starting in 2027.
Strategic Implications and Market Impact
John West, global head of analysis at Mergermarket, observed that the proposed combination would have established a comprehensive portfolio spanning knee and hip implants while addressing critical musculoskeletal gaps for both companies. However, the breakdown leaves Smith & Nephew to navigate ongoing financial pressures independently. The company has struggled with weak sales growth and cost-cutting initiatives over the past three years, with its share price having fallen 21% over the preceding 12 months against a 13% gain for the broader FTSE 100 index.
Following the collapse of the merger talks, J&J is pivoting toward alternative strategies for its orthopaedics unit. Last week, J&J executives indicated that the company is leaning heavily toward spinning off the orthopaedics business, which operates under DePuy Synthes, into a separately listed entity targeted for mid-2027. While the unit has also drawn private equity interest seeking a $20 billion valuation, no formal transaction has materialized, leaving both corporate giants to chart separate paths forward in the medical devices sector.